NEW YORK (360Dx) – Vermillion said today that it has received coverage for its OVA1 ovarian cancer test from the Louisiana and Arizona state Medicaid programs.
The company also signed coverage agreements with Joint Venture Hospital Laboratories to provide OVA1 as an in-network benefit to roughly 600,000 BlueCare Network of Michigan members and with QCA Health Plan of Arkansas (Qualchoice) to provide OVA1 coverage to roughly 87,000 lives in that state.
"We are pleased to expand the in-network coverage for OVA1 with the signing of these agreements," Fred Ferrara, Vermillion's COO, said in a statement. "These agreements increase coverage in strategic geographic areas and expand access to OVA1."
With the new coverage agreements, more than 97 million lives are contracted or have a positive policy determination for OVA1, Vermillion said.